The announcement of a class action lawsuit against Kyverna Therapeutics for alleged securities violations related to their IPO is likely to create negative sentiment among investors. Legal issues can lead to financial penalties and damage to reputation, which often result in a decline in stock prices. The high relevance and importance scores reflect the direct impact of the lawsuit on the company.